PODCAST:
April 22, 2026 ~ Chris Renwick and Lloyd Jackson speak with Dr. Philip Philip, co-leader of the Pancreatic Cancer Program at Henry Ford Health, about a promising new drug that may improve pancreatic cancer treatment.
Pancreatic cancer patients may have avenues of hope in the future, with three separate treatments for the disease showing promise in clinical trials.
Revolution Medicines recently shared that its pill, daraxonrasib, more than doubled a patient’s life expectancy over chemotherapy. Another experimental drug called elraglusib is being developed by Actuate Therapeutics, which also saw patients’ survival odds doubled while taking the medication.
In addition to these drugs, an mRNA vaccine is being developed by the companies BioNTech and Genentech, which recently moved into Phase 2 of the clinical trial for the vaccine.
